David L Fry

US Patent:

20040067942, Apr 8, 2004

Filed:

Aug 1, 2003

Appl. No.:

10/632281

Inventors:

William Elliott - Ann Arbor MI, US
David Fry - Ypsilanti MI, US

International Classification:

A61K031/7072
A61K031/5377
A61K031/337

US Classification:

514/234200, 514/050000, 514/449000

Abstract:

Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.

US Patent:

20050222163, Oct 6, 2005

Filed:

Mar 30, 2005

Appl. No.:

11/095442

Inventors:

Stephen Eck - Ann Arbor MI, US
David Fry - Ypsilanti MI, US
Judith Leopold - Ann Arbor MI, US

International Classification:

A61K031/519

US Classification:

514252160

Abstract:

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

US Patent:

20060293323, Dec 28, 2006

Filed:

Aug 14, 2006

Appl. No.:

11/464249

Inventors:

William Elliott - Ann Arbor MI, US
David Fry - Ypsilanti MI, US

International Classification:

A61K 31/5377
A61K 31/7072
A61K 31/7048
A61K 31/704
A61K 31/337
A61K 31/282
A61K 31/4745

US Classification:

514234200, 424649000, 514027000, 514034000, 514049000, 514449000, 514492000, 514283000

Abstract:

Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.

US Patent:

57212660, Feb 24, 1998

Filed:

Sep 26, 1994

Appl. No.:

8/312253

Inventors:

Stuart James Decker - Ann Arbor MI
David William Fry - Ypsilanti MI
James Marino Hamby - Ann Arbor MI
Alan Robert Saltiel - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A01N 4350

US Classification:

514398

Abstract:

Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of N,N'-piperazinylbis-�2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis�2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis�2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-�2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis�2-amino-1-imidazolin-2-yl)-2-imidazolines!.

US Patent:

D314150, Jun 6, 1989

Filed:

May 7, 1986

Appl. No.:

6/859895

Inventors:

David F. Fry - Birmingham MI
Louis J. Crosslen - Saukville WI
John L. Kraus - Shorewood WI

Assignee:

Chrysler Motors Corporation - Highland Park MI

US Classification:

D 6432

US Patent:

20190263811, Aug 29, 2019

Filed:

Oct 10, 2018

Appl. No.:

16/156880

Inventors:

- Boulder CO, US
David Fry - Boulder CO, US
Elizabeth A. McFaddin - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Julia Haas - Boulder CO, US
Tony P. Tang - Boulder CO, US
Yutong Jiang - Boulder CO, US

International Classification:

C07D 471/08
A61K 9/00
A61P 35/00

Abstract:

Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula III), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-hydroxy-4-(pyridin-2-ylmethyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula IV), and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, the application relates to novel crystalline forms of Formula I-IV and pharmaceutically acceptable salts thereof useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.